Loading...
01/10 19:57
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with record EPS, increased cash reserves, and improved operational efficiency. Positive developments include resolved G7 issues, a successful limited launch of the 15-day sensor, and growth across type 2 markets. Despite some deceleration in Q4 2025, the company maintains optimistic growth projections for 2026. The raised 2025 revenue guidance and strategic focus on innovation and market expansion further support a positive outlook. However, some concerns remain due to the lack of specific 2026 guidance and vague responses in the Q&A.
Organic Revenue Growth 20% year-over-year growth compared to Q3 2024, driven by category growth, CGM access expansion, and solid share performance in U.S. and international businesses.
Worldwide Revenue $1.21 billion, a 22% increase from $994 million in Q3 2024, attributed to organic growth and expanded market coverage.
U.S. Revenue $852 million, a 21% increase from $702 million in Q3 2024, driven by broader presence in primary care and new coverage in the non-insulin market.
International Revenue $357.4 million, a 22% increase year-over-year, with 18% organic growth. Growth driven by expanded access in regions like France and Canada.
Gross Profit $741.3 million or 61.3% of revenue, down from 63.0% in Q3 2024. Decline due to higher scrap rates at manufacturing facilities and increased scrutiny on supplied products.
Operating Expenses $468.4 million, up from $413.9 million in Q3 2024, reflecting increased R&D investment.
Operating Income $272.9 million or 22.6% of revenue, up from $212.0 million or 21.3% of revenue in Q3 2024, due to effective expense management.
Adjusted EBITDA $368.4 million or 30.5% of revenue, up from $300.1 million or 30.2% of revenue in Q3 2024, reflecting improved operational efficiency.
Net Income $242.5 million or $0.61 per share, marking the highest quarterly earnings per share in the company's history.
Cash and Cash Equivalents Greater than $3.3 billion, an increase of nearly $400 million during the quarter, supported by strong free cash flow and share repurchases.
DexCom Smart Basal: A new feature designed to simplify basal insulin titration and management for type 2 diabetes patients. It uses algorithms to identify optimal timing and dosage, aiming to improve adherence and reduce manual inputs for healthcare providers. Currently under FDA and CE Mark review.
Stelo: A product that has surpassed $100 million in revenue within its first year. It focuses on improving metabolic health and is being enhanced with software updates, broader distribution, and new partnerships. Plans for international expansion are underway.
G7 15-day system: A new product with finalized reimbursement contracts with Medicare and major commercial payers. Initial launch feedback is being gathered, with a broader rollout planned soon.
Type 2 diabetes coverage expansion: Coverage now includes nearly 6 million type 2 non-insulin lives in the U.S., representing about half of the type 2 NIT commercial population. Efforts are ongoing to expand coverage to the entire population of over 25 million Americans and internationally.
International market growth: Strong growth in markets like France and Canada due to expanded type 2 diabetes coverage. France has shown accelerating growth every quarter in 2025, and Canada has seen increased demand following new coverage in Ontario.
Gross margin challenges: Third-quarter gross margin was impacted by higher-than-expected scrap rates at manufacturing facilities, though improvements were noted compared to the second quarter. Efforts are ongoing to stabilize sensor supply and reduce costs.
Operational efficiencies: Transitioning back to cost-efficient shipping methods like ocean freight and maintaining focus on managing operating expenses despite increased R&D investment.
Customer experience enhancements: Introduction of 'My DexCom Account,' a new online portal for streamlined support and order tracking. Improvements in G7 sensor quality and customer service are ongoing.
Capital allocation strategy: Plans to settle $1.2 billion of convertible notes in cash and continue share repurchases, supported by a strong cash position of over $3.3 billion.
Supply Chain Challenges: Higher-than-expected scrap rates at manufacturing facilities and reliance on third-party components have led to deployment issues for sensors. Although the issue has been addressed, extra scrutiny on supplied products has increased costs and impacted gross margins.
Gross Margin Pressure: Gross profit margin decreased to 61.3% from 63.0% due to higher scrap rates and increased costs associated with ensuring product quality. This has created near-term financial pressure.
Regulatory and Approval Delays: The DexCom Smart Basal feature is still under review with the FDA and for CE Mark, which could delay its market availability and impact the company's ability to capture the basal insulin market.
Customer Experience Concerns: Complaints about G7 sensor performance, including Bluetooth connectivity and adhesive issues, have been noted. Although improvements have been made, these issues could impact customer satisfaction and brand reputation.
Market Expansion Risks: While international markets like France and Canada show growth, further expansion depends on securing broader type 2 diabetes coverage, which remains uncertain in some regions.
Economic and Financial Risks: The company plans to settle $1.2 billion of convertible notes in cash, which could strain financial flexibility despite a strong cash position. Additionally, reliance on expedited shipping earlier in the year increased costs.
Revenue Guidance: DexCom has raised its revenue guidance for 2025 to a range of $4.630 billion to $4.650 billion, representing approximately 15% growth for the year.
Gross Profit Margin Guidance: The company has lowered its 2025 non-GAAP gross profit margin guidance to approximately 61% due to additional scrap dynamics.
Operating Margin and Adjusted EBITDA Margin Guidance: DexCom is guiding to a non-GAAP operating margin range of 20% to 21% and an adjusted EBITDA margin range of 29% to 30%, with expectations to offset some gross margin pressure through continued operating expense leverage.
Product Launch - DexCom Smart Basal: DexCom Smart Basal, a titration module designed to optimize basal insulin management, is under review with the FDA and for CE Mark. Once approved, it will enhance the value proposition for type 2 basal insulin users and their physicians.
Product Launch - G7 15-day System: DexCom is preparing for the broader launch of its G7 15-day system, with reimbursement contracts finalized with Medicare, major commercial payers, and DME partners. The broader rollout is expected in the coming weeks.
International Expansion - Stelo: DexCom plans to extend its Stelo product to international markets in the near term, following its success in generating over $100 million in revenue within its first 12 months in the U.S.
Type 2 Diabetes Coverage Expansion: DexCom is working to expand CGM coverage for the type 2 diabetes population in the U.S. and globally, with ongoing randomized controlled trials (RCTs) to strengthen evidence for broader coverage.
Share Repurchase: We had a very strong free cash flow quarter, which helped us increase our cash and cash equivalents balance by nearly $400 million, even as we repurchased shares over the course of the quarter. This cash level provides us with significant flexibility. And given where our shares are currently priced, we plan to settle our upcoming $1.2 billion of convertible notes in cash. In addition, we plan to remain in the market this quarter, repurchasing additional shares. Even after settlement of this convert, we'll have plenty of cash on hand to assess ongoing capital allocation opportunities, including additional repurchases.
The earnings call highlights strong financial performance with record EPS, increased cash reserves, and improved operational efficiency. Positive developments include resolved G7 issues, a successful limited launch of the 15-day sensor, and growth across type 2 markets. Despite some deceleration in Q4 2025, the company maintains optimistic growth projections for 2026. The raised 2025 revenue guidance and strategic focus on innovation and market expansion further support a positive outlook. However, some concerns remain due to the lack of specific 2026 guidance and vague responses in the Q&A.
The earnings call and Q&A reveal strong financial performance and promising developments. Key positives include organic revenue growth, new product launches, FDA collaboration, and expanded PBM coverage. The Q&A highlights strategic initiatives, such as the G8 platform, type 2 user base expansion, and international growth. Despite some vague management responses, the overall sentiment is positive, supported by robust financial metrics and optimistic guidance. The stock is likely to react positively, with a potential increase of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
